an AGC kinase of the PKC family. Calcium-independent, phospholipid-dependent. Activated by inflammatory mediators and involved in nociceptive functions. PKC-epsilon null mice display decreased hypoxic pulmonary vasoconstriction. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, Ser/Thr (non-receptor); EC 188.8.131.52; Protein kinase, AGC; Kinase, protein; AGC group; PKC family; Eta subfamily
Cellular Component: Golgi apparatus; cytoskeleton; mitochondrion; perinuclear region of cytoplasm; endoplasmic reticulum; cytoplasm; plasma membrane; nucleus; cytosol
Molecular Function: actin monomer binding; protein serine/threonine kinase activity; calcium-independent protein kinase C activity; protein binding; signal transducer activity; protein kinase C activity; enzyme binding; metal ion binding; enzyme activator activity; ethanol binding; receptor activator activity; ATP binding
Biological Process: nerve growth factor receptor signaling pathway; apoptosis; response to morphine; positive regulation of lipid catabolic process; signal transduction; protein amino acid phosphorylation; positive regulation of MAPKKK cascade; lipopolysaccharide-mediated signaling pathway; cell adhesion; regulation of peptidyl-tyrosine phosphorylation; positive regulation of cytokinesis; epidermal growth factor receptor signaling pathway; platelet activation; positive regulation of I-kappaB kinase/NF-kappaB cascade; fibroblast growth factor receptor signaling pathway; positive regulation of synaptic transmission, GABAergic; positive regulation of insulin secretion; cell cycle; peptidyl-serine phosphorylation; positive regulation of actin filament polymerization; phospholipase C activation; cell division; release of sequestered calcium ion into cytosol; macrophage activation during immune response; innate immune response; blood coagulation
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.